Born from Akston, a leader in developing protein therapeutics for companion animal health, Diamune emerged to address a critical gap in human diabetes care. Leveraging Akston’s proprietary Ambifect® Fc-fusion protein platform, Diamune is dedicated to advancing innovative treatments for both type 1 and type 2 diabetes. Our mission is to revolutionize diabetes management through early intervention and long-acting therapies. With a strong foundation in scientific excellence and a commitment to improving patient outcomes, Diamune is poised to make a significant impact in the field of diabetes care.